These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 39141976)
1. CRISPR/Cas9-mediated suppression of A4GALT rescues endothelial cell dysfunction in a fabry disease vasculopathy model derived from human induced pluripotent stem cells. Shin YJ; Chae SY; Lee H; Fang X; Cui S; Lim SW; Lee KI; Lee JY; Li C; Yang CW; Chung BH Atherosclerosis; 2024 Oct; 397():118549. PubMed ID: 39141976 [TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model. Cui S; Shin YJ; Fang X; Lee H; Eum SH; Ko EJ; Lim SW; Shin E; Lee KI; Lee JY; Lee CB; Bae SK; Yang CW; Chung BH Transl Res; 2023 Aug; 258():35-46. PubMed ID: 36805562 [TBL] [Abstract][Full Text] [Related]
3. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells. Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984 [TBL] [Abstract][Full Text] [Related]
4. Generation of a GLA knock-out human-induced pluripotent stem cell line, KSBCi002-A-1, using CRISPR/Cas9. Kim YK; Yu JH; Min SH; Park SW Stem Cell Res; 2020 Jan; 42():101676. PubMed ID: 31841972 [TBL] [Abstract][Full Text] [Related]
5. Modeling of Fabry disease nephropathy using patient derived human induced pluripotent stem cells and kidney organoid system. Cui S; Fang X; Lee H; Shin YJ; Koh ES; Chung S; Park HS; Lim SW; Lee KI; Lee JY; Yang CW; Chung BH J Transl Med; 2023 Feb; 21(1):138. PubMed ID: 36814269 [TBL] [Abstract][Full Text] [Related]
6. Generation of a CRISPR/Cas9-corrected-hiPSC line (DDLABi001-A) from Fabry disease (FD)-derived iPSCs having α-galactosidase (GLA) gene mutation (c.803_806del). Choi JB; Seo D; Do HS; Han YM Stem Cell Res; 2023 Feb; 66():103001. PubMed ID: 36516658 [TBL] [Abstract][Full Text] [Related]
7. Imbalanced Production of Reactive Oxygen Species and Mitochondrial Antioxidant SOD2 in Fabry Disease-Specific Human Induced Pluripotent Stem Cell-Differentiated Vascular Endothelial Cells. Tseng WL; Chou SJ; Chiang HC; Wang ML; Chien CS; Chen KH; Leu HB; Wang CY; Chang YL; Liu YY; Jong YJ; Lin SZ; Chiou SH; Lin SJ; Yu WC Cell Transplant; 2017 Mar; 26(3):513-527. PubMed ID: 27938475 [TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-based GLA knockout to generate the female Fabry disease human induced pluripotent stem cell line MHHi001-A-15. Juchem M; Lehmann N; Behrens YL; Bär C; Thum T; Hoepfner J Stem Cell Res; 2024 Sep; 79():103478. PubMed ID: 38905814 [TBL] [Abstract][Full Text] [Related]
9. Reversal of the Inflammatory Responses in Fabry Patient iPSC-Derived Cardiovascular Endothelial Cells by CRISPR/Cas9-Corrected Mutation. Song HY; Yang YP; Chien Y; Lai WY; Lin YY; Chou SJ; Wang ML; Wang CY; Leu HB; Yu WC; Chien CS Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673551 [TBL] [Abstract][Full Text] [Related]
10. Endothelial Cell Dysfunction and Hypoxia as Potential Mediators of Pain in Fabry Disease: A Human-Murine Translational Approach. Klug K; Spitzel M; Hans C; Klein A; Schottmann NM; Erbacher C; Üçeyler N Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895103 [TBL] [Abstract][Full Text] [Related]
11. Generation of Song HY; Chien CS; Yarmishyn AA; Chou SJ; Yang YP; Wang ML; Wang CY; Leu HB; Yu WC; Chang YL; Chiou SH Cells; 2019 Apr; 8(4):. PubMed ID: 30965672 [TBL] [Abstract][Full Text] [Related]
12. Using CRISPR/Cas9-Mediated GLA Gene Knockout as an In Vitro Drug Screening Model for Fabry Disease. Song HY; Chiang HC; Tseng WL; Wu P; Chien CS; Leu HB; Yang YP; Wang ML; Jong YJ; Chen CH; Yu WC; Chiou SH Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27983599 [TBL] [Abstract][Full Text] [Related]
13. Modeling of endothelial cell dysfunction using human induced pluripotent stem cells derived from patients with end-stage renal disease. Kim KW; Shin YJ; Kim BM; Cui S; Ko EJ; Lim SW; Yang CW; Chung BH Kidney Res Clin Pract; 2021 Dec; 40(4):698-711. PubMed ID: 34781643 [TBL] [Abstract][Full Text] [Related]
14. α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease. Kang JJ; Kaissarian NM; Desch KC; Kelly RJ; Shu L; Bodary PF; Shayman JA Kidney Int; 2019 Jan; 95(1):149-159. PubMed ID: 30470436 [TBL] [Abstract][Full Text] [Related]
16. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease. Namdar M; Gebhard C; Studiger R; Shi Y; Mocharla P; Schmied C; Brugada P; Lüscher TF; Camici GG PLoS One; 2012; 7(4):e36373. PubMed ID: 22558451 [TBL] [Abstract][Full Text] [Related]
17. Generation of human induced pluripotent stem cell line MHHi029-A from a male Fabry disease patient carrying c.959A > T mutation. Jahn C; Juchem M; Sonnenschein K; Gietz A; Buchegger T; Lachmann N; Göhring G; Behrens YL; Bär C; Thum T; Hoepfner J Stem Cell Res; 2024 Jun; 77():103404. PubMed ID: 38552356 [TBL] [Abstract][Full Text] [Related]
18. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease. Choi S; Kim JA; Na HY; Cho SE; Park S; Jung SC; Suh SH Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):81-9. PubMed ID: 24158513 [TBL] [Abstract][Full Text] [Related]
19. Vascular Tumor Recapitulated in Endothelial Cells from hiPSCs Engineered to Express the van IJzendoorn DGP; Salvatori DCF; Cao X; van den Hil F; Briaire-de Bruijn IH; de Jong D; Mei H; Mummery CL; Szuhai K; Bovée JVMG; Orlova VV Cell Rep Med; 2020 Dec; 1(9):100153. PubMed ID: 33377124 [TBL] [Abstract][Full Text] [Related]
20. Gene and MicroRNA Profiling of Human Induced Pluripotent Stem Cell-Derived Endothelial Cells. Wang L; Su W; Du W; Xu Y; Wang L; Kong D; Han Z; Zheng G; Li Z Stem Cell Rev Rep; 2015 Apr; 11(2):219-27. PubMed ID: 25618294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]